Abstract:PURPOSE This study aims to appraise the therapeutic effectiveness of intravitreal injections anti-vascular endothelial growth factor (anti-VEGF) versus alternative therapies in managing radiation retinopathy (RR). DESIGN Systematic review and meta-analysis. METHODS We obtained comprehensive data retrieval using PubMed, Embase, Web of Science, Scopus, and the Cochrane Library from their inception until December 15, 2023. This review included randomized controlled trials (RCTs) and non-randomized studies (NRSs) reporting on best-corrected visual acuity (BCVA) among RR patients treated with intravitreal anti-VEGF. Study selection and data extraction were meticulously performed by two independent reviewers. The Cochrane Risk of Bias Tool 2.0 (RoB 2.0) and Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) scales were utilized for bias risk assessment. Quantification of heterogeneity was executed using Q, H, and I 2 statistics. The primary endpoint was the BCVA at the final observation point of each study. Secondary endpoints included central retinal thickness (CRT), foveal avascular zone (FAZ) area, and capillary density (CD) at the level of superficial capillary plexus. Subgroup analyses were undertaken to explore potential heterogeneity sources possibly due to treatment duration and study design. Sensitivity analyses were conducted to ascertain result stability. RESULTS This analysis incorporated 7 studies (including 3 RCTs) encompassing 922 patients afflicted with RR. Relative to other treatment modalities, intravitreal anti-VEGF therapy was associated with a statistically significant mean decrease in BCVA of -0.34 logMAR (95% CI: -0.39 to -0.30 logMAR; I 2 = 87.70%; P < .001), and a substantial reduction in CRT of -34.65 μm (95% CI: -50.70 to -18.60 μm; I 2 = 30.40%; P < .001). Additionally, a reduction in the FAZ area by -0.69 mm2 (95% CI: -0.91 to -0.46 mm2, I 2 = 0%; P < .001) was observed. A positive tendency was noted in CD at the superficial capillary plexus between anti-VEGF and other therapeutic interventions. CONCLUSIONS Intravitreal anti-VEGF injections, in comparison to other treatments, demonstrate superior efficacy in enhancing BCVA and reducing CRT, thereby underscoring the potential of anti-VEGF in ameliorating radiation retinopathy outcomes. However, the conclusions are constrained by the incorporation of data from some NRSs and the small sample sizes.

Risk of retinal vein occlusion in colorectal cancer patients receiving anti-vascular endothelial growth factors – a population-based cohort study

Construction of Risk Assessment Model for Venous Thromboembolism after Colorectal Cancer Surgery: A Chinese Single-Center Study

A Meta-Analysis of Cardiovascular Events Associated with Intravitreal Anti-VEGF Treatment in Patients with Retinal Vein Occlusion

Retinal vascular events and relationship to CANCER development

A retrospective study assessing the factors associated with visual outcome in retinal vein occlusion patients after anti-VEGF therapy

Risk of Ischemic Stroke, Hemorrhagic Stroke, and All-Cause Mortality in Retinal Vein Occlusion: A Nationwide Population-Based Cohort Study

Prognosis and factors related to anti-VEGF therapy in patients with retinal vein occlusion and concomitant carotid artery disease

Analyze of Factors and Prognosis of Eyes Lost to Follow-Up in Retinal Vein Occlusive Disease Patients Receiving Anti-Vascular Endothelial Growth Factor Therapy

Central retinal vein occlusion in patients with metastatic solid tumors on tyrosine kinase inhibitors: a report of case series and literature review

A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics

Chorioretinal venous anastomosis for non-ischemic retinal vein occlusion

Rationale and Design of a Prospective, Multicenter, Cohort Study on the Evaluation of Postoperative Venous ThromboEmbolism Incidence in Patients with ColoRectal Cancer (CRC-VTE Trial)

A Risk of Venous Thromboembolism Algorithm As a Predictor of Venous Thromboembolism in Patients with Colorectal Cancer

Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis

Prevalence and risk factors of retinal vein occlusion in individuals with diabetes: The kailuan eye study

Chronic Inflammation and Colorectal Cancer: the Role of Vascular Endothelial Growth Factor

An observational study of vascular endothelial growth factor inhibitors as second-line treatment for metastatic colorectal cancer treated with bevacizumab plus FOLFIRI beyond progression: the association with RAS mutation and tumor sidedness

Refocusing on the Etiology and Pathology of Retinal Vein Occlusion to Guide Clinical Practice

Efficacy of Intravitreal Injections Anti-Vascular Endothelial Growth Factor Treatment for Radiation Retinopathy: A Systematic Review and Meta-analysis

Anti-VEGF therapy possibly extends survival in patients with colorectal brain metastasis by protecting patients from neurological disability

Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review